Abstract
Henry Hrdlicka, David Rosenblum
Abstract
Rights: UNKNOWN · cc-by-nc · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020
Gut microbiota: a new piece in understanding hepatocarcinogenesis
10.1016/j.canlet.2020.01.002 · 2020
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment
10.1126/science.1240527 · 2013
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
10.1186/s40425-019-0650-9 · 2019
10.3390/cancers13194824
10.3390/cancers13194824
Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance
10.1038/s41586-023-06026-3 · 2023
Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy
10.1126/science.abc9113 · 2021
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
10.1126/science.abc3421 · 2020
A defined commensal consortium elicits CD8 T cells and anticancer immunity
10.1038/s41586-019-0878-z · 2019
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
10.1126/science.aan3706 · 2018
No additional external references are available.